Entinostat (SNDX-275) for the treatment of non-small cell lung cancer

Raez, Luis E.; Rolfo, Christian; Ruiz, Rossana

dc.contributor.author	Ruiz, Rossana
dc.contributor.author	Raez, Luis E.
dc.contributor.author	Rolfo, Christian
dc.date.accessioned	2019-02-06T14:52:34Z
dc.date.available	2019-02-06T14:52:34Z
dc.date.issued	2015
dc.identifier.uri	https://hdl.handle.net/20.500.12866/5312
dc.description.abstract	INTRODUCTION: Epigenetic aberrations play an important role in lung carcinogenesis. Chromatin deacetylation is a fundamental mechanism of gene silencing. Histone deacetylase (HDAC) inhibitors are an emerging class of antineoplastic agents that enable the accessibility of DNA to transcription factors, therefore promoting gene expression. Entinostat is a selective HDAC inhibitor that has shown anti-neoplastic activity and tolerability in hematologic and solid tumors, including lung cancer. AREAS COVERED: This article summarizes the pharmacokinetics, pharmacodynamics, mechanisms of action, safety, tolerability, pre-clinical studies and clinical trials of the HDAC inhibitor entinostat, as a novel promissory agent for the treatment of NSCLC. EXPERT OPINION: The field of targeted therapy has increased in lung cancer. However, even now with the current FDA-approved agents, < 15% of patients benefit from these interventions and we are still far from curing lung cancer. New targets are needed. Either in combination with cytotoxic drugs, epigenetic therapy or other molecular targeted drugs, entinostat represents a new potential agent for the treatment of non-small cell carcinomas. However, the preliminary safety and efficacy results from several clinical trials still need to be validated in large Phase III trials.	en_US
dc.language.iso	eng
dc.publisher	Taylor and Francis
dc.relation.ispartofseries	Expert Opinion on Investigational Drugs
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	Humans	en_US
dc.subject	Animals	en_US
dc.subject	epigenetics	en_US
dc.subject	Antineoplastic Agents/adverse effects/pharmacology/therapeutic use	en_US
dc.subject	Benzamides/adverse effects/pharmacology/therapeutic use	en_US
dc.subject	Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology	en_US
dc.subject	entinostat	en_US
dc.subject	Epigenesis, Genetic	en_US
dc.subject	histone deacetylase	en_US
dc.subject	Histone Deacetylase Inhibitors/adverse effects/pharmacology/therapeutic use	en_US
dc.subject	Lung Neoplasms/drug therapy/genetics/pathology	en_US
dc.subject	Molecular Targeted Therapy	en_US
dc.subject	non-small cell lung cancer	en_US
dc.subject	Pyridines/adverse effects/pharmacology/therapeutic use	en_US
dc.title	Entinostat (SNDX-275) for the treatment of non-small cell lung cancer	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1517/13543784.2015.1056779
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.01.05
dc.relation.issn	1744-7658